SPRYARS Pharmaceuticals, Inc.
$4.57-56% 1Y
$4.57
$4.0752 weeks$13.06
Is the price fair?
What SPRY's price assumes
ARS Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 8.06× revenue.
8.06
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 13.0
Price / book · as of 2026-Q1
- EV / sales
- 8.79
EV / sales
Details›
- Price / bookas of 2026-Q1
- 13.0
- EV / EBIToperating margin −185%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 8.79
- Market capitalisation
- $454M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.